期刊
VACCINES
卷 2, 期 1, 页码 1-14出版社
MDPI AG
DOI: 10.3390/vaccines2010001
关键词
HIV-1 vaccines; immune tolerance; broadly neutralizing antibody; B-cell lineage design; HIV-1 vaccine strategy
资金
- NIH
- Bill and Melinda Gates Foundation
In this brief review, we discuss immune tolerance as a factor that determines the magnitude and quality of serum antibody responses to HIV-1 infection and vaccination in the context of recent work. We propose that many conserved, neutralizing epitopes of HIV-1 are weakly immunogenic because they mimic host antigens. In consequence, B cells that strongly bind these determinants are removed by the physiological process of immune tolerance. This structural mimicry may represent a significant impediment to designing protective HIV-1 vaccines, but we note that several vaccine strategies may be able to mitigate this evolutionary adaptation of HIV and other microbial pathogens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据